- Home
- EONR vs ENSC Comparison
EONR vs ENSC Comparison
Compare EONR & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EONR
- ENSC
- Stock Information
- Founded
- EONR 2020
- ENSC 2003
- Country
- EONR United States
- ENSC United States
- Employees
- EONR N/A
- ENSC N/A
- Industry
- EONR
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- EONR
- ENSC Health Care
- Exchange
- EONR NYSE
- ENSC Nasdaq
- Market Cap
- EONR 8.0M
- ENSC 7.9M
- IPO Year
- EONR N/A
- ENSC N/A
- Fundamental
- Price
- EONR $0.62
- ENSC $5.40
- Analyst Decision
- EONR Strong Buy
- ENSC
- Analyst Count
- EONR 1
- ENSC 0
- Target Price
- EONR $4.50
- ENSC N/A
- AVG Volume (30 Days)
- EONR 1.3M
- ENSC 26.4K
- Earning Date
- EONR 03-04-2025
- ENSC 03-14-2025
- Dividend Yield
- EONR N/A
- ENSC N/A
- EPS Growth
- EONR N/A
- ENSC N/A
- EPS
- EONR N/A
- ENSC N/A
- Revenue
- EONR $21,714,016.00
- ENSC $4,421,404.00
- Revenue This Year
- EONR N/A
- ENSC $89.78
- Revenue Next Year
- EONR $78.80
- ENSC N/A
- P/E Ratio
- EONR N/A
- ENSC N/A
- Revenue Growth
- EONR N/A
- ENSC 40.41
- 52 Week Low
- EONR $0.51
- ENSC $2.12
- 52 Week High
- EONR $6.00
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- EONR N/A
- ENSC 35.78
- Support Level
- EONR N/A
- ENSC $5.34
- Resistance Level
- EONR N/A
- ENSC $6.14
- Average True Range (ATR)
- EONR 0.00
- ENSC 0.43
- MACD
- EONR 0.00
- ENSC -0.04
- Stochastic Oscillator
- EONR 0.00
- ENSC 9.49
About EONR EON RESOURCES INC
EON Resources Inc is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. Its current focus is as an upstream energy company producing oil and gas properties in the Permian Basin.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.